# colorectal cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 54420
- Completion tokens: 24186
- Reasoning tokens: 16608
- Total tokens: 78606
- API requests reported: 4
- Elapsed seconds: 80.159
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 3/5; original repeat 4; model vendor: xAI

---
**1. Overall biological interpretation**  
The prognostic results highlight a coherent theme in which colorectal tumor cells with preserved mitochondrial oxidative phosphorylation and glyoxylate metabolism associate with improved overall survival, whereas those exhibiting EMT-driven motility and AKT/PI3K-like signaling confer risk. Multiple risk-associated genes (54 total) and protective-associated genes (46 total) converge on bioenergetic flexibility versus invasive plasticity, consistent with CRC biology in which metabolic rewiring influences tumor progression and therapy response under the supplied HR-based associations.

**2. Core biological programs**  

**Program name:** Glyoxylate and dicarboxylate metabolism  
**Direction or prognostic association:** Protective (HR < 1)  
**Major supporting genes:** GLYCTK, CS, ASL, OGDHL  
**The most appropriate standardized pathway:** KEGG Glyoxylate and dicarboxylate metabolism  
**Explanation of why the supporting genes collectively indicate this biological program:** These enzymes enable metabolic flexibility by converting glyoxylate to succinate and supporting anaplerosis; their consistent protective association indicates that efficient glyoxylate pathway activity may enhance tumor adaptability or reduce oxidative stress, influencing OS.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (four genes with HR 0.69–0.75 and FDR ≤ 0.0744); pathway annotation support; limitations include reliance on a subset of genes and absence of formal enrichment statistic.

**Program name:** Oxidative phosphorylation and ATP production  
**Direction or prognostic association:** Protective (HR < 1)  
**Major supporting genes:** NDUFA9, ATP23, ATP5G1, ATP5B, CS  
**The most appropriate standardized pathway:** KEGG Oxidative phosphorylation  
**Explanation of why the supporting genes collectively indicate this biological program:** These genes encode electron-transport-chain subunits, ATP synthase components, and metabolic enzymes that maintain bioenergetic homeostasis; their protective association suggests preserved mitochondrial function correlates with better OS by supporting tumor energy demands or limiting metabolic stress.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (multiple genes with HR < 1 and FDR 0.0066–0.0593); pathway support; limitations include potential general tumor hypoxia confounding rather than CRC-specific mechanisms and lack of independent-cohort HR statistics.

**Program name:** Epithelial-mesenchymal transition and cell motility  
**Direction or prognostic association:** Risk-associated (HR > 1)  
**Major supporting genes:** ZEB1-AS1, DCBLD2, TPM4, NIN, ITGBL1  
**The most appropriate standardized pathway:** Hallmark EMT or KEGG Focal adhesion  
**Explanation of why the supporting genes collectively indicate this biological program:** These genes promote mesenchymal transition, cytoskeletal remodeling, and migratory signaling; their risk association indicates that EMT activation facilitates invasion and metastasis, driving poorer OS.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (five genes with HR 1.28–1.41 and FDR ≤ 0.0306); published literature support for several; limitations include indirect gene-function mapping and non-coding gene names reducing mechanistic specificity.

**Program name:** PI3K/AKT signaling and microtubule organization  
**Direction or prognostic association:** Mixed (AKT3 risk-associated; supporting GO terms regulatory)  
**Major supporting genes:** AKT3 (risk), plus GO-annotated genes in selected set (ABL2, CS)  
**The most appropriate standardized pathway:** KEGG Gastric cancer (shared with CRC) or GO Regulation of Phospholipase C Activity / Microtubule anchoring  
**Explanation of why the supporting genes collectively indicate this biological program:** AKT3 promotes survival signaling; GO terms link selected genes to phospholipase C regulation and microtubule anchoring, suggesting integration of signaling and cytoskeletal dynamics that modulate motility and therapy resistance.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset for AKT3 (HR = 1.318, FDR = 0.0388) plus STRING edges (42 total); pathway/GO annotation; limitations include indirect mapping for non-AKT3 genes and no independent-cohort statistics.

**3. Key genes and interaction modules**  
**INHBB (risk, HR = 1.433, FDR = 0.001093):** Potential role in TGF-β signaling and tumor progression within EMT program; literature links high expression to poor CRC prognosis. Relationship: indirect regulatory interaction with EMT-related genes via SMAD pathways.  
**ZEB1-AS1 (risk, HR = 1.372, FDR = 0.008647):** Core EMT regulator; role in mesenchymal transition and invasion within the EMT program. Relationship: regulatory interaction with DCBLD2 and TPM4 (co-expression or pathway co-membership).  
**NDUFA9 (protective, HR = 0.6886, FDR = 0.008647):** Mitochondrial complex I subunit; role in the oxidative phosphorylation program. Relationship: pathway co-membership with ATP5 genes.  
**CDX2 (protective, HR = 0.7478, FDR = 0.035501):** Intestinal differentiation factor; role in suppressing Wnt/β-catenin signaling. Relationship: indirect relationship via differentiation networks; supported by published CRC literature.  
**NT5E (risk, HR = 1.313, FDR = 0.039390):** CD73 ecto-enzyme; role in immune evasion and nucleotide metabolism. Relationship: putative regulatory interaction with immune-related genes.  
**AKT3 (risk, HR = 1.318, FDR = 0.038754):** Serine/threonine kinase; role in PI3K/AKT signaling and survival pathways. Relationship: STRING direct physical interaction with PIK3CA, PHLPP1/2, and PIK3R1.  
**GLYCTK (protective, HR = 0.7093, FDR = 0.020342):** Glycerate kinase; role in glyoxylate metabolism. Relationship: STRING direct physical interaction with GRHPR and TKFC.  
**TPM4 (risk, HR = 1.364, FDR = 0.008909):** Tropomyosin isoform; role in cytoskeletal stability and motility within EMT program. Relationship: co-expression with NIN.  
**DCBLD2 (risk, HR = 1.408, FDR = 0.008647):** Discoidin domain receptor; role in signaling and EMT. Relationship: regulatory interaction with ZEB1-AS1.  
**CS (protective, HR = 0.7545, FDR = 0.038754):** Citrate synthase; role in both glyoxylate metabolism and oxidative phosphorylation. Relationship: STRING co-membership with ILVBL and ACSS2.

**4. Validation priorities**  
**Mechanistic hypothesis:** Functional validation of INHBB in CRC cell lines or patient-derived organoids. Why it deserves prioritization: strongest FDR among risk genes and direct literature support for poor-prognosis role. Evidence provided by current dataset (HR and FDR) plus disease-association literature. External evidence supports the hypothesis but does not prove causality in OS. Most appropriate next step: CRISPR knockout and assessment of proliferation/invasion/metastasis. Classification: Supported hypothesis.  

**Biomarker:** Independent-cohort validation of CDX2 and INHBB as OS-associated markers. Why it deserves prioritization: CDX2 has established CRC differentiation role; INHBB has high statistical significance. Evidence provided by current dataset (HR values) plus published CRC studies. Most appropriate next step: testing in TCGA or GEO survival cohorts. Classification: Supported hypothesis.  

**Interaction / network hypothesis:** Experimental confirmation of STRING interactions among mitochondrial (NDUFA9, ATP23) and EMT (TPM4, ZEB1-AS1) genes. Why it deserves prioritization: STRING records 42 edges among selected genes. Evidence provided by current dataset plus STRING records. External evidence is annotation-based only. Most appropriate next step: co-immunoprecipitation or proximity ligation assays. Classification: Exploratory hypothesis.  

**Confounding or composition check:** Assess tumor purity (e.g., via ESTIMATE or deconvolution algorithms) and correlate with gene-expression levels or HRs, especially for mitochondrial genes. Why it deserves prioritization: mitochondrial genes are sensitive to stromal/immune admixture in tumor tissue. Evidence provided by current dataset (expression and HR values). External evidence argues against specific confounding in the supplied data but notes general tissue-composition issues. Most appropriate next step: laser-capture microdissection or IHC-based purity scoring. Classification: Confounding or composition check.  

**Mechanistic hypothesis:** Functional validation of AKT3 within PI3K/AKT signaling in CRC models. Why it deserves prioritization: significant risk association (FDR 0.0388) and GO/STRING links to signaling modules. Evidence provided by current dataset. External evidence includes pathway annotations. Most appropriate next step: siRNA knockdown and assessment of survival-related phenotypes. Classification: Supported hypothesis.

**5. Evidence grounding**  
All major programs rest on direct evidence from the input dataset (HR, P, FDR values) for gene associations; KEGG/GO annotations supply program-level context; STRING records provide network evidence (42 edges); disease-association evidence derives from published literature for genes such as INHBB (Europe PMC 41992239) and CDX2 (PubMed 30631044); expression/tissue-specific evidence is limited to the colorectal tumor context; no independent-cohort statistics are available, so external records serve only as plausibility support rather than replication. Protein-interaction evidence (STRING) is annotation-based and not independent of the dataset. No conflicting evidence noted; all claims are supported where dataset or external records exist.

**6. Limitations and alternative explanations**  
- Potential batch or platform effects in the microarray data (presence of PROBE_ identifiers).  
- Unaddressed tumor purity and cell-composition differences, which could bias mitochondrial gene signals.  
- Unknown treatment exposure (chemotherapy, targeted therapy) that may confound OS associations.  
- Small number of genes reaching strict FDR thresholds (only 8 with FDR ≤ 0.01), limiting statistical power.  
- Association-versus-causation ambiguity inherent to HR-based prognostic modeling.  

Tumor-purity confounding could be experimentally distinguished by comparing HRs in microdissected tumor versus stromal-rich samples or by multivariable regression adjusting for purity scores derived from bulk RNA-seq. The current dataset provides a robust starting point for hypothesis generation in CRC prognosis but requires independent validation to establish clinical utility.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=22, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
